JP2018528199A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528199A5
JP2018528199A5 JP2018510352A JP2018510352A JP2018528199A5 JP 2018528199 A5 JP2018528199 A5 JP 2018528199A5 JP 2018510352 A JP2018510352 A JP 2018510352A JP 2018510352 A JP2018510352 A JP 2018510352A JP 2018528199 A5 JP2018528199 A5 JP 2018528199A5
Authority
JP
Japan
Prior art keywords
crystal form
group
powder
independently selected
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018510352A
Other languages
English (en)
Japanese (ja)
Other versions
JP6940039B2 (ja
JP2018528199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/096200 external-priority patent/WO2017032289A1/en
Publication of JP2018528199A publication Critical patent/JP2018528199A/ja
Publication of JP2018528199A5 publication Critical patent/JP2018528199A5/ja
Application granted granted Critical
Publication of JP6940039B2 publication Critical patent/JP6940039B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018510352A 2015-08-25 2016-08-22 Parp阻害剤の製造方法、結晶型、及びその使用 Expired - Fee Related JP6940039B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/088003 2015-08-25
CN2015088003 2015-08-25
PCT/CN2016/096200 WO2017032289A1 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Publications (3)

Publication Number Publication Date
JP2018528199A JP2018528199A (ja) 2018-09-27
JP2018528199A5 true JP2018528199A5 (cg-RX-API-DMAC7.html) 2019-09-26
JP6940039B2 JP6940039B2 (ja) 2021-09-22

Family

ID=58099633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510352A Expired - Fee Related JP6940039B2 (ja) 2015-08-25 2016-08-22 Parp阻害剤の製造方法、結晶型、及びその使用

Country Status (15)

Country Link
US (1) US10457680B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341375B1 (cg-RX-API-DMAC7.html)
JP (1) JP6940039B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180041748A (cg-RX-API-DMAC7.html)
CN (2) CN112521390A (cg-RX-API-DMAC7.html)
AU (1) AU2016312011B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003634B1 (cg-RX-API-DMAC7.html)
CA (1) CA2994895A1 (cg-RX-API-DMAC7.html)
EA (1) EA037366B1 (cg-RX-API-DMAC7.html)
IL (2) IL296835A (cg-RX-API-DMAC7.html)
MX (1) MX385450B (cg-RX-API-DMAC7.html)
NZ (1) NZ739876A (cg-RX-API-DMAC7.html)
TW (1) TWI736550B (cg-RX-API-DMAC7.html)
WO (1) WO2017032289A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800765B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171883T1 (hr) 2011-12-31 2018-01-12 BeiGene, Ltd., Mourant Ozannes, Corporate Services (Cayman) Limited Kondenzirani tetra ili penta-ciklički dihidrodiazepinokarbazoloni kao parp inhibitori
IL296835A (en) 2015-08-25 2022-11-01 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
CN110087730B (zh) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
WO2019015561A1 (en) * 2017-07-17 2019-01-24 Beigene, Ltd. TREATMENT OF CANCERS USING A COMBINATION COMPRISING INHIBITORS OF PARP, TEMOZOLOMIDE AND / OR RADIOTHERAPY
MX2020012259A (es) 2018-05-18 2021-01-29 Novartis Ag Formas cristalinas de un inhibidor de tlr7/tlr8.
AU2019275722A1 (en) * 2018-06-01 2020-11-12 Beigene, Ltd. Maintenance therapy of a PARP inhibitor in treating gastric cancer
USD926356S1 (en) * 2019-03-14 2021-07-27 Tuanfang Liu Battery for electronic cigarette
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法
CN113402502B (zh) * 2019-05-16 2022-10-14 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体制备的物料组合体系
CN111171001B (zh) * 2019-05-16 2022-04-29 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的结晶方法
JP2022534093A (ja) * 2019-05-31 2022-07-27 ベイジーン リミテッド Parp阻害剤ペレット製剤及びその調製方法
CN112007011B (zh) * 2019-05-31 2024-07-23 百济神州(苏州)生物科技有限公司 一种parp抑制剂微丸胶囊及其制备工艺
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2218110T3 (es) 1999-01-11 2004-11-16 Agouron Pharmaceuticals, Inc. Inhibidores triciclicos de poli(adp-ribosa)polimerasas.
EP1339402B1 (en) * 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
KR100697746B1 (ko) * 2003-01-09 2007-03-22 화이자 인코포레이티드 키나제 저해제로서의 디아제피노인돌 유도체
PT2767537T (pt) 2008-08-06 2017-07-17 Medivation Technologies Inc Inibidores de di-hidropiridoftalazinona de poli(adp-ribose)polimerase (parp)
HRP20171883T1 (hr) 2011-12-31 2018-01-12 BeiGene, Ltd., Mourant Ozannes, Corporate Services (Cayman) Limited Kondenzirani tetra ili penta-ciklički dihidrodiazepinokarbazoloni kao parp inhibitori
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
IL296835A (en) 2015-08-25 2022-11-01 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
CN110087730B (zh) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
WO2019015561A1 (en) 2017-07-17 2019-01-24 Beigene, Ltd. TREATMENT OF CANCERS USING A COMBINATION COMPRISING INHIBITORS OF PARP, TEMOZOLOMIDE AND / OR RADIOTHERAPY
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法

Similar Documents

Publication Publication Date Title
JP2018528199A5 (cg-RX-API-DMAC7.html)
JP2018511634A5 (cg-RX-API-DMAC7.html)
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
JP2005503386A5 (cg-RX-API-DMAC7.html)
JPWO2003008421A1 (ja) アミジン誘導体の製造方法
JP2002519422A (ja) パロキセチンメタンスルホネート
ES2575000T3 (es) Proceso mejorado para la preparación de ambrisentano
JP2020033359A5 (cg-RX-API-DMAC7.html)
JP6779972B2 (ja) 呼吸器合胞体ウイルス(rsv)感染症の処置のためのn−[(3−アミノ−3−オキセタニル)メチル]−2−(2,3−ジヒドロ−1,1−ジオキシド−1,4−ベンゾチアゼピン−4(5h)−イル)−6−メチル−4−キナゾリンアミンの結晶形
JP2003286287A (ja) 塩酸エピナスチン高融点型結晶の製造法
EP2350055A1 (en) Lenalidomide solvates and processes
WO2018117267A1 (ja) 置換ピペリジン化合物の塩
JP6225998B2 (ja) インドリン化合物の製造方法
CN102675395B (zh) 醋酸乌利司他的多晶型及其制备方法
AU2011284341A1 (en) N-Methylformamide solvate of dasatinib
EP3565819A2 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
JPWO2016175305A1 (ja) アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法
JP2007524569A (ja) ナテグリニドの結晶形
CN110372635B (zh) 氢溴酸沃替西汀α晶型的制备方法
JP2006511614A (ja) ナテグリニドの多形性形状
TW201643142A (zh) 製備白克列之方法
JP7340534B2 (ja) トレプロスチニルジエタノールアミン塩の多形形態bを製造するための方法
CN109535060B (zh) 一种刺猬通路抑制剂及其制备方法和应用
CA3048771C (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2013013594A1 (zh) 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的无定形物及其制备方法